Skip to main content
Article thumbnail
Location of Repository

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

By C Ziske, C Schlie, M Gorschlüter, A Glasmacher, U Mey, J Strehl, T Sauerbruch and I G H Schmidt-Wolf
Topics: Clinical
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2394360
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1996). A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.
    2. (1996). CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer.
    3. (1998). Gemcitabine–a safety review. Anticancer Drugs 9: 191–201 Ahlgren JD
    4. (1996). Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101–105 Cox D
    5. (1994). The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.